AU2018321926B2 - Ocular pharmaceutical compositions - Google Patents

Ocular pharmaceutical compositions Download PDF

Info

Publication number
AU2018321926B2
AU2018321926B2 AU2018321926A AU2018321926A AU2018321926B2 AU 2018321926 B2 AU2018321926 B2 AU 2018321926B2 AU 2018321926 A AU2018321926 A AU 2018321926A AU 2018321926 A AU2018321926 A AU 2018321926A AU 2018321926 B2 AU2018321926 B2 AU 2018321926B2
Authority
AU
Australia
Prior art keywords
compound
active agent
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018321926A
Other languages
English (en)
Other versions
AU2018321926A1 (en
Inventor
Marc H. Levin
Alan Verkman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2018321926A1 publication Critical patent/AU2018321926A1/en
Application granted granted Critical
Publication of AU2018321926B2 publication Critical patent/AU2018321926B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2018321926A 2017-08-24 2018-08-24 Ocular pharmaceutical compositions Active AU2018321926B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762549872P 2017-08-24 2017-08-24
US62/549,872 2017-08-24
PCT/US2018/048025 WO2019040919A1 (en) 2017-08-24 2018-08-24 OCULAR PHARMACEUTICAL COMPOSITIONS

Publications (2)

Publication Number Publication Date
AU2018321926A1 AU2018321926A1 (en) 2020-03-12
AU2018321926B2 true AU2018321926B2 (en) 2023-09-21

Family

ID=65439930

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018321926A Active AU2018321926B2 (en) 2017-08-24 2018-08-24 Ocular pharmaceutical compositions

Country Status (8)

Country Link
US (3) US11839616B2 (enExample)
EP (1) EP3672598A4 (enExample)
JP (1) JP2020531511A (enExample)
KR (1) KR20200044873A (enExample)
CN (1) CN111629730A (enExample)
AU (1) AU2018321926B2 (enExample)
CA (1) CA3073718A1 (enExample)
WO (1) WO2019040919A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6938510B2 (ja) 2015-12-24 2021-09-22 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｃｆｔｒ制御因子及びこの使用方法
US11839616B2 (en) 2017-08-24 2023-12-12 The Regents Of The University Of California Ocular pharmaceutical compositions
US11957413B2 (en) * 2019-08-06 2024-04-16 University of Pittsburgh—of the Commonwealth System of Higher Education Solitary wave-based trans-lid tonometer
EP4069195A1 (en) * 2019-12-05 2022-10-12 Vanda Pharmaceuticals Inc. Ophthalmic pharmaceutical compositions
JP2023541261A (ja) * 2020-09-10 2023-09-29 バンダ・ファーマシューティカルズ・インコーポレイテッド Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法
WO2025179141A1 (en) * 2024-02-22 2025-08-28 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112951A1 (en) * 2015-12-24 2017-06-29 The Regents Of The University Of California Cftr regulators and methods of use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
JPS62126178A (ja) 1985-11-26 1987-06-08 Mitsubishi Petrochem Co Ltd 新規トリアジン誘導体及びこれを含む除草剤
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
AU5433594A (en) 1992-11-19 1994-06-08 Dainippon Pharmaceutical Co. Ltd. 3,4-dihydro-1-(2-hydroxyphenyl)-2(1h)-quinoxalinone derivative and related compound
US6403598B1 (en) * 1998-01-30 2002-06-11 R-Tech Ueno, Ltd. Ophthalmic composition
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
IL137655A0 (en) 1998-03-31 2001-10-31 Warner Lambert Co Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
JP4794793B2 (ja) 1999-12-28 2011-10-19 ファーマコペイア， インコーポレイテッド Ｎ−ヘテロ環ＴＮＦ−α発現阻害剤
IL160984A0 (en) 2001-09-21 2004-08-31 Reddy Us Therapeutics Inc Triazine derivatives and pharmaceutical compositions containing the same
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
HK1080074A1 (zh) 2002-10-01 2006-04-21 Johnson & Johnson Pharmaceutical Research & Development, Inc. 作为酪氨酸蛋白激酶抑制剂的4，6-二氨基取代-2-[氧基或氨氧基]-[1，3，5]三嗪
JP2006528640A (ja) 2003-07-22 2006-12-21 ニューロジェン・コーポレーション 置換ピリジン−２−イルアミン類縁体
ES2631362T3 (es) 2004-01-30 2017-08-30 Vertex Pharmaceuticals Incorporated Moduladores de transportadores de casete de unión a ATP
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
DE102004023332A1 (de) 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
WO2007095812A1 (en) 2006-02-27 2007-08-30 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted [1,3,5] triazine compounds, their processes for preparation and uses thereof
CA2657093A1 (en) 2006-07-07 2008-01-10 Steven P. Govek Bicyclic heteroaryl inhibitors of pde4
KR101352709B1 (ko) 2007-05-22 2014-01-16 아스테라스 세이야쿠 가부시키가이샤 1위 치환 테트라히드로이소퀴놀린 화합물
US20090105240A1 (en) 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
EP2231624A4 (en) 2007-12-21 2011-07-06 Progenics Pharm Inc TRIAZINE AND CORRESPONDING COMPOUNDS WITH ANTIVIRAL EFFECT, COMPOSITIONS AND METHOD THEREFOR
JP5618837B2 (ja) 2008-03-05 2014-11-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ インスリン分泌刺激剤としてのキノキサリノン誘導体、それらを得る方法および糖尿病を治療するためのそれらの使用
CN102227430A (zh) 2008-10-23 2011-10-26 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
FR2958645B1 (fr) 2010-04-09 2012-08-31 Commissariat Energie Atomique Hemi-anticorps a auto-assemblage
CA2797118C (en) 2010-04-22 2021-03-30 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
WO2012092471A2 (en) 2010-12-29 2012-07-05 Development Center For Biotechnology Novel tubulin inhibitors and methods of using the same
KR20150095925A (ko) 2012-12-19 2015-08-21 노파르티스 아게 Cftr 억제제로서의 트리시클릭 화합물
WO2015018823A1 (en) * 2013-08-08 2015-02-12 Galapagos Nv Thieno[2,3-c]pyrans as cftr modulators
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
JP6716687B2 (ja) 2015-09-11 2020-07-01 イオン−トフ テクノロジーズ ゲーエムベーハー 二次イオン質量分析計及び二次イオン質量分析方法
US10035962B2 (en) * 2015-12-21 2018-07-31 Exxonmobil Research And Engineering Company Trim dewaxing of distillate fuel
AU2016377782B2 (en) 2015-12-24 2021-07-29 The Regents Of The University Of California CFTR regulators and methods of use thereof
CN108699040B (zh) 2015-12-24 2021-08-10 加利福尼亚大学董事会 Cftr调节剂及其使用方法
KR20180128390A (ko) 2015-12-24 2018-12-03 레스피버트 리미티드 인돌리논 화합물과 섬유성 질환의 치료에서 이의 용도
US11839616B2 (en) 2017-08-24 2023-12-12 The Regents Of The University Of California Ocular pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112951A1 (en) * 2015-12-24 2017-06-29 The Regents Of The University Of California Cftr regulators and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lee, S. et al.; J. Med. Chem., 60, 1210-1218 (2017). DOI: 10.1021/acs.jmedchem.6b01792 *

Also Published As

Publication number Publication date
US20240156828A1 (en) 2024-05-16
US20250367207A1 (en) 2025-12-04
US20210154201A1 (en) 2021-05-27
EP3672598A1 (en) 2020-07-01
AU2018321926A1 (en) 2020-03-12
EP3672598A4 (en) 2021-04-28
CA3073718A1 (en) 2019-02-28
WO2019040919A1 (en) 2019-02-28
US11839616B2 (en) 2023-12-12
RU2020111560A (ru) 2021-09-24
KR20200044873A (ko) 2020-04-29
RU2020111560A3 (enExample) 2021-10-29
CN111629730A (zh) 2020-09-04
JP2020531511A (ja) 2020-11-05

Similar Documents

Publication Publication Date Title
AU2018321926B2 (en) Ocular pharmaceutical compositions
ES2972099T3 (es) Formulación oftálmica
US11192869B2 (en) CFTR regulators and methods of use thereof
US12391654B2 (en) CFTR regulators and methods of use thereof
KR20060100440A (ko) 각결막 장해 치료제
CN103249400B (zh) 用于治疗青光眼和高眼压症的腺苷a1激动剂
ES2389566T3 (es) Agente preventivo o terapéutico para tratar un transtorno de la córnea y la conjuntiva
WO2016208961A1 (ko) 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
Felix et al. Pro-secretory activity and pharmacology in rabbits of an aminophenyl-1, 3, 5-triazine CFTR activator for dry eye disorders
RU2818087C2 (ru) Офтальмологические фармацевтические композиции
JPH1036255A (ja) 眼圧降下用点眼剤
KR20130108376A (ko) 신경 보호 작용을 갖는 약제 배합

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)